Canaccord Genuity Reaffirms Their Buy Rating on Regeneron (REGN)
Canaccord Genuity analyst John Newman maintained a Buy rating on Regeneron today and set a price target of $1,057.00.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Newman is an analyst with an average return of -0.5% and a 39.39% success rate. Newman covers the Healthcare sector, focusing on stocks such as Arcellx Inc, Regeneron, and Compass Therapeutics.
In addition to Canaccord Genuity, Regeneron also received a Buy from Citi’s Geoff Meacham in a report issued on February 13. However, on February 10, RBC Capital maintained a Hold rating on Regeneron (NASDAQ: REGN).
Based on Regeneron’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.88 billion and a net profit of $844.6 million. In comparison, last year the company earned a revenue of $3.79 billion and had a net profit of $917.7 million
Read More on REGN:
Disclaimer & DisclosureReport an Issue
- The Week That Was, The Week Ahead: Macro and Markets, Feb. 15
- Regeneron Advances REGN7508 Into Phase 3 To Tackle Cancer-Linked Blood Clots
- Sanofi and Regeneron Advance Itepekimab Bet With Completed Phase 2 Bronchiectasis Trial
- Regeneron and Sanofi Advance Kevzara Into Polymyalgia Rheumatica, Eyeing New Growth Channel
- Regeneron highlights expanding portfolio, pipeline at AAAI
